Literature DB >> 20976632

Aggressive sporadic histiocytic sarcoma with immunoglobulin heavy chain gene rearrangement and t(14;18).

Eiko Hayase1, Mitsutoshi Kurosawa, Masakatsu Yonezumi, Sachiko Suzuki, Hiroaki Suzuki.   

Abstract

Histiocytic sarcoma (HS) is a rare but aggressive malignant neoplasm of histiocytic lineage with a poor prognosis. Immunohistochemically, the neoplastic cells are positive for CD163, CD68, and lysozyme, and negative for B and T cell markers. However, molecular studies on the origin of the neoplastic cells remain inconclusive. A 54-year-old woman was admitted to our hospital because of painful swelling of the left knee. Examination revealed generalized lymphadenopathy and splenomegaly. HS was diagnosed according to morphologic and immunohistochemical features observed on biopsy of the left inguinal lymph node. The tumor demonstrated a clonal immunoglobulin heavy chain gene rearrangement and a clonal cytogenetic abnormality including t(14;18) which was confirmed by fluorescence in situ hybridization analysis showing the IgH/BCL2 fusion gene. The neoplastic cells were negative for PAX5, a B cell associated transcription factor, and positive for CEBPβ, a transcription factor mediating macrophage and myeloid differentiation. Positron emission tomography showed disseminated areas of increased 18F-fluorodeoxyglucose uptake in multiple lymph nodes, the liver, spleen, both lungs, both kidneys, and many bony sites. The patient received localized irradiation therapy followed by chemotherapy, she failed to respond and died of the disease progression. The case findings suggest lineage promiscuity or plasticity related to the pathogenesis of HS.

Entities:  

Mesh:

Year:  2010        PMID: 20976632     DOI: 10.1007/s12185-010-0704-8

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  22 in total

1.  Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/Pax5 pathway.

Authors:  Duonan Yu; David Allman; Michael H Goldschmidt; Michael L Atchison; John G Monroe; Andrei Thomas-Tikhonenko
Journal:  Blood       Date:  2002-10-24       Impact factor: 22.113

2.  Expression of CD163 (hemoglobin scavenger receptor) in normal tissues, lymphomas, carcinomas, and sarcomas is largely restricted to the monocyte/macrophage lineage.

Authors:  TuDung T Nguyen; Erich J Schwartz; Robert B West; Roger A Warnke; Daniel A Arber; Yasodha Natkunam
Journal:  Am J Surg Pathol       Date:  2005-05       Impact factor: 6.394

3.  True histiocytic lymphoma of the stomach associated with low-grade B-cell mucosa-associated lymphoid tissue (MALT)-type lymphoma.

Authors:  T Alvaro; R Bosch; M T Salvadó; M A Piris
Journal:  Am J Surg Pathol       Date:  1996-11       Impact factor: 6.394

4.  Histiocytic sarcoma: a study of five cases including the histiocyte marker CD163.

Authors:  Jeffrey A Vos; Susan L Abbondanzo; Carol L Barekman; Joann W Andriko; Markku Miettinen; Nadine S Aguilera
Journal:  Mod Pathol       Date:  2005-05       Impact factor: 7.842

5.  Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases.

Authors:  S A Pileri; T M Grogan; N L Harris; P Banks; E Campo; J K C Chan; R D Favera; G Delsol; C De Wolf-Peeters; B Falini; R D Gascoyne; P Gaulard; K C Gatter; P G Isaacson; E S Jaffe; P Kluin; D M Knowles; D Y Mason; S Mori; H-K Müller-Hermelink; M A Piris; E Ralfkiaer; H Stein; I-J Su; R A Warnke; L M Weiss
Journal:  Histopathology       Date:  2002-07       Impact factor: 5.087

6.  High frequency of clonal immunoglobulin receptor gene rearrangements in sporadic histiocytic/dendritic cell sarcomas.

Authors:  Wei Chen; Sean K Lau; Dean Fong; Jun Wang; Endi Wang; Daniel A Arber; Lawrence M Weiss; Qin Huang
Journal:  Am J Surg Pathol       Date:  2009-06       Impact factor: 6.394

7.  Histiocytic sarcoma: PET-CT evaluation of a rare entity.

Authors:  Emel Yaman; Banu Ozturk; Ozlem Erdem; Nahide Gokcora; Ugur Coskun; Omer Uluoglu; Mustafa Benekli
Journal:  Ann Nucl Med       Date:  2008-11-04       Impact factor: 2.668

8.  Conversion of mature B cells into T cells by dedifferentiation to uncommitted progenitors.

Authors:  César Cobaleda; Wolfram Jochum; Meinrad Busslinger
Journal:  Nature       Date:  2007-09-12       Impact factor: 49.962

9.  Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant.

Authors:  Muneer H Abidi; Isaacson Tove; Rami B Ibrahim; Dan Maria; Edward Peres
Journal:  Am J Hematol       Date:  2007-10       Impact factor: 10.047

Review 10.  Pax5: the guardian of B cell identity and function.

Authors:  César Cobaleda; Alexandra Schebesta; Alessio Delogu; Meinrad Busslinger
Journal:  Nat Immunol       Date:  2007-05       Impact factor: 25.606

View more
  7 in total

1.  Rosai-Dorfman Disease Harboring an Activating KRAS K117N Missense Mutation.

Authors:  Vignesh Shanmugam; Elizabeth Margolskee; Michael Kluk; Tamara Giorgadze; Attilio Orazi
Journal:  Head Neck Pathol       Date:  2016-02-27

Review 2.  Imaging features of primary extranodal histiocytic sarcoma: report of two cases and a review of the literature.

Authors:  Sachin Shyamsunder Saboo; Katherine M Krajewski; Atul B Shinagare; Jyothi P Jagannathan; Jason L Hornick; Nikhil Ramaiya
Journal:  Cancer Imaging       Date:  2012-08-10       Impact factor: 3.909

3.  Cytogenetics findings in a histiocytic sarcoma case.

Authors:  J M Alonso-Dominguez; M Calbacho; M Talavera; C Villalon; L Abalo; J V Garcia-Gutierrez; S Lozano; M Tenorio; J Villarrubia; J Lopez-Jimenez; M T Ferro
Journal:  Case Rep Hematol       Date:  2012-06-03

4.  Rare myeloid sarcoma with KMT2A (MLL)-ELL fusion presenting as a vaginal wall mass.

Authors:  Haiyan Bao; Juehua Gao; Yi-Hua Chen; Jessica K Altman; Olga Frankfurt; Amanda L Wilson; Madina Sukhanova; Qing Chen; Xinyan Lu
Journal:  Diagn Pathol       Date:  2019-03-28       Impact factor: 2.644

5.  Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups.

Authors:  Caoimhe Egan; Alina Nicolae; Justin Lack; Hye-Jung Chung; Shannon Skarshaug; Thu Anh Pham; Winnifred Navarro; Zied Abdullaev; Nadine S Aguilera; Liqiang Xi; Svetlana Pack; Stefania Pittaluga; Elaine S Jaffe; Mark Raffeld
Journal:  Haematologica       Date:  2019-08-22       Impact factor: 9.941

6.  Primary splenic histiocytic sarcoma complicated with prolonged idiopathic thrombocytopenia and secondary bone marrow involvement: a unique surgical case presenting with splenomegaly but non-nodular lesions.

Authors:  Sohsuke Yamada; Takashi Tasaki; Naoko Satoh; Atsunori Nabeshima; Shohei Kitada; Hirotsugu Noguchi; Kozue Yamada; Morishige Takeshita; Yasuyuki Sasaguri
Journal:  Diagn Pathol       Date:  2012-10-17       Impact factor: 2.644

Review 7.  Canine Histiocytic Malignancies-Challenges and Opportunities.

Authors:  Katherine Kennedy; Rachael Thomas; Matthew Breen
Journal:  Vet Sci       Date:  2016-01-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.